365997-34-8

Basic information

• Product Name: 1S,3R,4S)-(+)-4-azido-3-[(tert-butoxycarbonyl)aMino]cyclohexanecarboxylic acid ethyl ester
• Synonyms: 1S,3R,4S)-(+)-4-azido-3-[(tert-butoxycarbonyl)aMino]cyclohexanecarboxylic acid ethyl ester;ethyl (1S,3R,4S)-4-azido-3-{[(tert-butoxy)carbonyl]amino}cyclohexane-1-carboxylate;Cyclohexanecarboxylic acid,4-azido-3-[[(1,1-dimethylethoxy)carbonyl]amino]-, ethyl ester,(1S,3R,4S)-
• CAS NO: 365997-34-8
• Molecular Formula: C₁₄H₂₄N₄O₄
• Molecular Weight: 312.36476
• Mol File: 365997-34-8.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Dichloromethane; Ethyl Acetate
• CAS DataBase Reference: 1S,3R,4S)-(+)-4-azido-3-[(tert-butoxycarbonyl)aMino]cyclohexanecarboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1S,3R,4S)-(+)-4-azido-3-[(tert-butoxycarbonyl)aMino]cyclohexanecarboxylic acid ethyl ester(365997-34-8)
• EPA Substance Registry System: 1S,3R,4S)-(+)-4-azido-3-[(tert-butoxycarbonyl)aMino]cyclohexanecarboxylic acid ethyl ester(365997-34-8)

Safety Data

• Hazardous Substances Data: 365997-34-8(Hazardous Substances Data)

Usage

Uses

Ethyl (1S,3R,4S)-4-Azido-3-(tert-butoxycarbonylamino)cyclohexane-1-carboxylate is an intermediate in the synthesis of Edoxaban-d6 (E555522), the isotope labelled analog of Edoxaban (E555520); an anticoagulant drug which acts as a direct factor Xa inhibitor.

Upstream product

• 139893-81-5 (1S,4S,5S)-4-bromo-6-oxabicyclo<3.2.1>octan-7-one 
• 5708-19-0 (1S)-3-cyclohexenecarboxylic acid 
• 4771-80-6 1,2,5,6-tetrahydrobenzoic acid 
• 929693-34-5 ethyl (1S,3R,4R)-3-amino-4-hydroxycyclohexanecarboxylate 
• 67976-82-3 (1S)-3-cyclohexene-1-carboxylic acid (R)-(+)-α-methylbenzylamine salt 
• 365997-31-5 (1S,3S,6R)-7-oxabicyclo[4.1.0]heptane-3-carboxylic acid ethyl ester 
• 123536-66-3 (1S,4S,5S)-4-iodo-6-oxabicyclo<3.2.1>octan-7-one 
• 365997-33-7 ethyl (1S,3R,4R)-3-(tert-butoxycarbonylamino)-4-hydroxycyclohexane-1-carboxylate 
• 365997-36-0 (1S,3R,4R)-3-[(tert-butoxycarbonyl)amino]-4-[(methylsulfonyl)oxy]cyclohexanecarboxylic acid ethyl ester 

Downstream Products

• 365998-33-0 ethyl (1S,3R,4S)-4-{[(benzyloxy)carbonyl]amino}-3-[(tert-butoxycarbonyl)amino]cyclohexanecarboxylate 
• 1255529-53-3 (1S,2R,4R)-2-[(tert-butoxycarbonyl)amino]-4-[(dimethylamino)carbonyl]cyclohexylcarbamic acid benzyl ester 
• 480450-69-9 tert-butyl N-[(1R,2S,5S)-2-azido-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate 
• 480452-36-6 carbamic acid, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxoacetyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-1,1-dimethylethyl ester 
• 480449-70-5 edoxaban 
• 480449-71-6 [14C]-Edoxaban tosylate 
• 480449-84-1 ethyl (1S,3R,4S)-4-amino-3-[(tert-butoxycarbonyl)amino]-cyclohexanecarboxylate 

Relevant articles and documents

Preparation method of edoxaban tosylate and isomers thereof

The invention discloses a preparation method of edoxaban tosylate and isomers thereof. By taking a compound (I) and a compound (II) as starting materials, the method can be used to prepare any one ofhigh-purity edoxaban tosylate (1S, 2R, 4S), edoxaban tosylate enantiomers (1R, 2S, 4R), edoxaban tosylate epimers (1R, 2R, 4S) and edoxaban tosylate epimers (1S, 2S, 4R). Effective guarantee is provided for process research and quality control of the edoxaban tosylate bulk drug and related preparations, the preparation method is suitable for commercialization, the produced edoxaban tosylate bulk drug is high in purity and has great significance and practical value, and the production of the edoxaban tosylate bulk drug and the control of drug quality are facilitated.

An efficient stereoselective synthesis of six stereoisomers of 3, 4-diaminocyclohexane carboxamide as key intermediates for the synthesis of factor Xa inhibitors

An efficient stereoselective route for the preparation of six stereoisomers of tert-butyl ((1R, 2S, 5S)-2-amino-5-(dimethylcarbamoyl)cyclohexyl)carbamate 1 starting from simple 3-cyclohexene-1-carboxylic acid has been described. Stereochemistry of the tit

OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME

The invention is directed to a process for producing intermediates of a compound which exhibits an activated blood coagulation factor Xa inhibitory action and which is a useful preventive and a therapeutic agent for thrombotic diseases. The intermediate production process is represented by the following reaction scheme.